Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret A.S.
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. In addition, it manufactures, trades, imports and exports of all kinds of human medicines and health products. The company was incorporated in 1997 and is headquartered in Çankaya, Turkey.
Leadership team data not yet available for this company.
We're expanding our GCC coverage — check back soon.
AGM Notice - Annual General Meeting Scheduled for May 2026
Apr 5, 2026
Board of Directors Approves Dividend Distribution for 2025
Mar 20, 2026
Gen Ilac ve Saglik Urunleri A.S. Announces 2025 Full Year Financial Results
Mar 15, 2026
Appointment of New Independent Board Member
Feb 10, 2026
Gen Ilac Completes Strategic Acquisition of Regional Pharmaceutical Distributor
Jan 25, 2026
Third Quarter 2025 Financial Results Released
Nov 14, 2025
Interim Dividend Distribution Approved by Board
Sep 30, 2025
Half Year 2025 Financial Results Announcement
Aug 28, 2025
Related Party Transaction Disclosure - Supply Agreement with Affiliate
Aug 12, 2025
Resignation of Board Member - Dr. Ahmet Kaya
Jul 22, 2025
Metrics not yet available.
Poor
8-factor live score
SouqData provides data for informational purposes only. This does not constitute financial advice, a personal recommendation, or an offer to buy or sell any security. Information may contain errors or be outdated. Always verify data independently and consult a licensed financial adviser before making investment decisions.
Get unlimited access to 180+ insight pages, AI copilot, deep research reports, watchlists, portfolio tracking, and the full 210-column screener across 11 MENA exchanges.
